Gynecologic Cancer | Norton Healthcare

Indication: Gynecologic Cancer

A Phase 1b/2, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination with Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients with Advanced Solid Tumors

Sub-indication: Gynecologic Cancer

Drug Study

Principal Investigator: Mary Gordinier, M.D.
Norton Cancer Institute

Sponsor: Sumitomo Dainippon Pharma Oncology, Inc.

Email for more information: GYN-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.